Recent molecular research highlights the EP300 Notch signaling pathway as a critical regulator in oral squamous cell carcinoma (OSCC). This malignancy remains a significant health challenge globally, particularly in India where tobacco use contributes to high incidence rates. Scientists have focused on the EP300 protein because it drives tumorigenesis, though the exact mechanisms remained elusive until recently.

Understanding EP300 Upregulation in Oral Cancer

Researchers used bioinformatics and molecular techniques to profile EP300 expression in various OSCC cell lines. Notably, the study found that EP300 expression levels were significantly higher in cancerous cells compared to healthy tissue. Furthermore, high expression of this protein correlates strongly with poor clinical outcomes and reduced survival rates in patients. Consequently, these findings establish EP300 as a potential biomarker for disease progression. Moreover, the study demonstrates a close relationship between this upregulation and the activation of Notch signals.

Therapeutic Potential of the EP300 Notch Signaling Pathway

To explore therapeutic possibilities, the researchers performed knockdown experiments using RT-PCR and Western blot. Consequently, knocking down EP300 successfully inhibited the proliferation of OSCC cells and arrested the cell cycle. Moreover, the intervention promoted programmed cell death, or apoptosis, while suppressing epithelial-mesenchymal transition (EMT). These processes are essential for cancer metastasis and recurrence. Therefore, targeting the EP300 Notch signaling pathway provides a promising strategy to manage aggressive oral cancers and prevent recurrence.

Rescue Assays and Clinical Implications

Additionally, the study investigated whether Notch activation could reverse the therapeutic effects of EP300 suppression. By using Valproic acid (VPA), a known Notch activator, the team observed a partial reversal of the suppressed proliferation and EMT. This interaction confirms that EP300 drives OSCC development primarily by modulating Notch signals. These results suggest that combined therapeutic approaches targeting this axis might improve treatment efficacy for refractory OSCC cases. Furthermore, clinicians may eventually use EP300 levels to stratify patients into high-risk groups for more intensive monitoring.

FAQs

How does EP300 influence oral cancer growth?

EP300 acts as an oncogenic driver in oral squamous cell carcinoma. Its upregulation correlates with poor patient prognosis, increased cell proliferation, and the promotion of epithelial-mesenchymal transition (EMT).

Can the Notch pathway be a target for OSCC therapy?

Yes, inhibiting the Notch signaling pathway through EP300 knockdown significantly reduces tumor cell growth and induces apoptosis, suggesting its potential as a targeted therapeutic strategy.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for professional healthcare. Always seek the advice of a qualified physician or other health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wang H et al. Inhibition of the EP300/Notch Signaling Pathway Regulates Proliferation and Apoptosis in Oral Squamous Cell Carcinoma. J Oral Pathol Med. 2026 Jun 16. doi: 10.1111/jop.70159. PMID: 42299711.

Kim SY et al. The role of p300 in the tumor progression of oral squamous cell carcinoma. J Oral Pathol Med. 2015;44(3):203-209. doi: 10.1111/jop.12227.

Chai AWY et al. Multifactorial Contribution of Notch Signaling in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020;12(5):1183. doi: 10.3390/cancers12051183.